Biopharma giant Gilead Sciences will shut down its office in Seattle’s Eastlake neighborhood, the company confirmed to ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Global biopharmaceutical company Gilead Sciences Inc. (Nasdaq: GILD) is closing its office in Seattle and laying off 72 ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Data shows Latino and Black people make up nearly 30% of the Bay Area population but only about 10% of active medical ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...